Skip to content
HomeLatest newsOur heritageMeet Dr. Paul Janssen: a legend in pharmacology
Dr. Paul Janssen, a Belgian Physician and Founder of Janssen

Meet Dr. Paul Janssen: a legend in pharmacology

When Janssen Pharmaceuticals merged with Johnson & Johnson in the early 1960s, a fruitful collaboration that continues to this day was born. Learn about the man who coined over 100 patents and developed dozens of life-changing medications.

Share Article
share to

Putting people first is at the heart of Johnson & Johnson’s company Credo. And that wouldn’t be possible if not for the remarkable people who have trailblazed at the company since its founding in 1886.

In the latest installment of our “Employee Blast from the Past” series, we’re putting the spotlight on Paul Janssen, without whom the Janssen Pharmaceutical Companies of Johnson & Johnson—and the groundbreaking work that comes out of their labs—wouldn’t exist.The Employee ...
Paul Janssen, Namesake, the Janssen Pharmaceutical Companies of Johnson & Johnson, 1961-1991

Why he’s so legendary ...
Janssen, the son of a doctor, was born in Belgium in 1926. And although his father’s vocation no doubt inspired his own passion for medicine, he was driven toward research after the loss of his 4-year-old sister to tuberculous meningitis. Despite modest financial means, he boldly founded his own independent research lab at the age of 27.

Early on, Janssen recognized the relationship between a compound’s chemical structure and its action as a medicine and, in turn, synthesized many revolutionary drug compounds, including a breakthrough treatment for psychotic disorders. To further grow his lab’s potential, Janssen decided to merge his company with Johnson & Johnson, a move that was finalized in February 1962.

The rest, as they say, is history.

Dr. Paul Janssen and Koen Andres

Janssen with scientist Koen Andries, who later discovered a new drug to treat tuberculosis

Johnson & Johnson’s resources dovetailed perfectly with the pace of Janssen’s research enterprise, which at the time of Janssen’s passing in 2003, had grown to 34 foreign affiliates and a workforce of 16,000—and an impressive portfolio of noteworthy medications, including Imodium®, a potentially lifesaving treatment for diarrhea.

As Janssen made the rounds of his research labs, he was known for relentlessly asking: “What’s new?” So it’s only fitting that, after his death, the company made his dream discovery: the first new treatment for tuberculosis in more than 40 years.

What most people don’t know ...
After setting up the first western pharmaceutical company in China, Janssen became involved in the fate of one of their national treasures: the historic Xian Terracotta Army, whose façades were being destroyed by mold.

Janssen helped protect and preserve the statues by using antifungal medicine from his lab—and the Janssen Pharmaceutical Companies of Johnson & Johnson continues to aid in the preservation of these priceless artifacts.

When you’ve been innovating for over 135 years …

Johnson & Johnson has a virtual museum where you can learn more fun facts about its rich history.

More from Johnson & Johnson

What to know about We All Belong: 2023 DEI Impact Review

The annual report details how Johnson & Johnson is harnessing the power of diversity, equity and inclusion to provide better care around the world.

Giving the gift of sight

In Kenya, around 1.5 million people—including children—contend with visual impairment or blindness. Sight For Kids, Johnson & Johnson’s global eye-care partnership, is devoted to changing these stats, one vision screening at a time.

Inside the development of a revolutionary treatment for blood cancers

In 2014, a Johnson & Johnson therapy gained approval for the treatment of a type of B-cell malignancy—increasing survival rates and changing the way scientists approach cancer treatment. These 8 milestone moments tell the transformational story.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.